View Cart  
Theqmnweeklybulletin

Feb. 3, 2012

Vol. 4 No. 5

View Archived Issues

Sign Up Now

Keeping up to Date With International Conflict Regs Is a Must for Drugmakers

In many countries, independent experts help make approval decisions on YOUR products. Read More

Ben Venue Manufacturing Pause Extended to Q4 2012

Troubled sterile injectable maker Ben Venue Laboratories is extending its voluntary manufacturing pause as major reconstruction in one wing of its now shuttered Bedford, Ohio, plant will take nine months to complete. Read More

Process Validation Is Not the Place to Cut Corners, Experts Advise

Reducing costs in tough economic times is tempting, but drug and device manufacturers should not cut corners when it comes to process validation — especially after release of the FDA’s final process validation guidance, experts advise. Read More

Don’t Drown in Wave of Device Adverse Events in EU

Device-related adverse events are increasing in the EU, with the most recent numbers showing a 13 percent rise in the UK to 10,280 in 2010. Read More

Packaging Error Prompts Pfizer Recall of Birth Control Drug

Pfizer is voluntarily recalling 14 lots of its oral contraceptive Lo/Ovral-28 and 14 lots of the norgestrel and ethinyl estradiol generic product as some blister packs may be missing tablets or displaying tablets out of sequence. Read More

RI Consultants Gets 483 for Weak Device History Record Procedures

RI Consultants, a maker of radiotherapy devices, was handed a Form 483 for a dearth of device history records and for not identifying the training needs of personnel at its Nashua, N.H., plant. Read More

FDA Stresses Risk Assessments in Q&A on cGMP, Process Controls

Drugmakers befuddled by manufacturing failures, such as product contamination by microorganisms, are urged to perform risk assessments and take preventive action, the FDA says. Read More

Laser Firms Get FDA Warnings Due to Website Claims, Procedural Flaws

Online claims that overstated the medical benefits of infrared lasers for home use landed three devicemakers in hot water with the FDA. Read More